pyrazines has been researched along with hydroxyurea in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 7 (70.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, W; Hai, T; Mora-Jensen, H; Perez-Galan, P; Ron, D; Trenkle, W; Wang, Q; Weniger, MA; Wiestner, A; Wolford, C; Ye, Y | 1 |
| Brem, GJ; Brüning, A; Mylonas, I | 1 |
| Abboud, MR; Achebe, MM; Alkindi, S; Ataga, KI; Brown, RC; Diuguid, DL; El-Beshlawy, A; Elghandour, A; Gordeuk, VR; Hassab, H; Hoppe, CC; Howard, J; Intondi, A; Kanter, J; Lehrer-Graiwer, J; Nduba, V; Telfer, P; Tonda, M; Tong, B; Tsitsikas, DA; Vichinsky, E; Ware, RE | 1 |
| Steinberg, MH | 1 |
| Herity, LB; Lowe, DK; Rodriguez, LR; Vaughan, DM | 1 |
| Ataga, KI; Brugnara, C; Staffa, SJ; Stocker, JW | 1 |
| Ballas, SK; Gordeuk, VR; Hankins, JS; Kuypers, FA; Thompson, AA; Vichinsky, E | 1 |
| Çanak, B; Eşkazan, AE | 1 |
| Anderson, AR; Fuqua, T; Muschick, K; Stoker-Postier, C | 1 |
| Fasipe, TA; Kavanagh, PL; Wun, T | 1 |
2 review(s) available for pyrazines and hydroxyurea
| Article | Year |
|---|---|
Voxelotor: A Novel Treatment for Sickle Cell Disease.
Topics: Anemia, Sickle Cell; Benzaldehydes; Female; Hematologic Agents; Hemoglobins; Humans; Hydroxyurea; Male; Pyrazines; Pyrazoles; Treatment Outcome; Young Adult | 2021 |
Sickle Cell Disease: A Review.
Topics: Adult; Anemia, Sickle Cell; Antibodies, Monoclonal, Humanized; Antisickling Agents; Benzaldehydes; Child; Glutamine; Hematologic Agents; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Infant, Newborn; Neonatal Screening; Pain; Pyrazines; Pyrazoles; Transition to Adult Care; United States | 2022 |
1 trial(s) available for pyrazines and hydroxyurea
| Article | Year |
|---|---|
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Benzaldehydes; Biomarkers; Child; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Hemoglobin, Sickle; Hemoglobins; Hemolysis; Humans; Hydroxyurea; Intention to Treat Analysis; Male; Middle Aged; Polymerization; Pyrazines; Pyrazoles; Young Adult | 2019 |
7 other study(ies) available for pyrazines and hydroxyurea
| Article | Year |
|---|---|
ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Adaptor Proteins, Vesicular Transport; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line; Cell Line, Tumor; Endoplasmic Reticulum; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Hydrazones; Hydroxyurea; Neoplasms; Proteasome Endopeptidase Complex; Pyrazines; Transcription, Genetic; Ubiquitin | 2009 |
Eeyarestatin causes cervical cancer cell sensitization to bortezomib treatment by augmenting ER stress and CHOP expression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Synergism; Endoplasmic Reticulum Stress; Female; HeLa Cells; Humans; Hydrazones; Hydroxyurea; Membrane Potential, Mitochondrial; Pyrazines; Transcription Factor CHOP; Ubiquitin; Up-Regulation; Uterine Cervical Neoplasms | 2013 |
Treating sickle cell anemia: A new era dawns.
Topics: Anemia, Sickle Cell; Antibodies, Monoclonal, Humanized; Benzaldehydes; Child; Fetal Hemoglobin; Forecasting; Gene Expression Regulation; Genetic Therapy; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Hypoxia, Brain; Infant; P-Selectin; Pain; Pyrazines; Pyrazoles; Therapies, Investigational | 2020 |
Haemoglobin response to senicapoc in patients with sickle cell disease: a re-analysis of the Phase III trial.
Topics: Acetamides; Anemia, Sickle Cell; Benzaldehydes; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Hemoglobins; Hemolysis; Humans; Hydroxyurea; Intermediate-Conductance Calcium-Activated Potassium Channels; Pyrazines; Pyrazoles; Trityl Compounds | 2021 |
Time to rethink haemoglobin threshold guidelines in sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Benzaldehydes; Blood Transfusion; Blood Viscosity; Genetic Therapy; Hematocrit; Hematopoietic Stem Cell Transplantation; Hemoglobin, Sickle; Hemoglobins; Humans; Hydroxyurea; Practice Guidelines as Topic; Pyrazines; Pyrazoles | 2021 |
Spotlight Commentary - Voxelotor: A new kid on the block in the treatment of sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Benzaldehydes; Humans; Hydroxyurea; Pyrazines; Pyrazoles | 2022 |
Real-world data on voxelotor to treat patients with sickle cell disease.
Topics: Adolescent; Adult; Aged; Anemia, Sickle Cell; Benzaldehydes; Bilirubin; Child; Female; Humans; Hydroxyurea; Male; Middle Aged; Pyrazines; Pyrazoles; Retrospective Studies; Young Adult | 2022 |